Ischaemic and haemorrhagic stroke associated with non-Vitamin K antagonist oral anticoagulants and warfarin use in patients with atrial fibrillation: A nationwide cohort study

European Heart Journal

Volumn 38, Issue 12, 2017, Pages 907-915

  Staerk, Laila ^a   Fosbøl, Emil Loldrup ^b,c   Lip, Gregory Y H ^d   Lamberts, Morten ^a,b   Bonde, Anders Nissen ^a   Torp Pedersen, Christian ^e   Ozenne, Brice ^f   Gerds, Thomas Alexander ^f   Gislason, Gunnar Hilmar ^a,c,g,h   Olesen, Jonas Bjerring ^a,i  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b Mental Health Center Glostrup   (Denmark)

^c Department of Cardiovascular Epidemiology and Research   (Denmark)

^d UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^e AALBORG UNIVERSITY HOSPITAL   (Denmark)

^f UNIVERSITY OF COPENHAGEN   (Denmark)

^g UNIVERSITY OF COPENHAGEN   (Denmark)

^h UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

ⁱ HILLERØD HOSPITAL   (Denmark)

Author keywords

Apixaban; Atrial fibrillation; Dabigatran; NOACs; Rivaroxaban; Stroke

Indexed keywords

ANTIVITAMIN K; APIXABAN; DABIGATRAN; RIVAROXABAN; ANTICOAGULANT AGENT; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE; VITAMIN K GROUP; WARFARIN;

AGED; ARTICLE; ATRIAL FIBRILLATION; ATTRIBUTABLE RISK; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIAC PATIENT; CARDIOVASCULAR DISEASE ASSESSMENT; CARDIOVASCULAR RISK; CHA2DS2 VASC SCORE; COHORT ANALYSIS; COMORBIDITY; DISEASE REGISTRY; FEMALE; FOLLOW UP; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; ICD-10; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PRESCRIPTION; PRIORITY JOURNAL; ADULT; ANTAGONISTS AND INHIBITORS; CEREBROVASCULAR ACCIDENT; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPLICATION; DENMARK; MIDDLE AGED; MULTICENTER STUDY; STATISTICS AND NUMERICAL DATA; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; BRAIN ISCHEMIA; COHORT STUDIES; DABIGATRAN; DENMARK; FEMALE; HOSPITALIZATION; HUMANS; INTRACRANIAL HEMORRHAGES; MALE; MIDDLE AGED; PYRAZOLES; PYRIDONES; RIVAROXABAN; STROKE; VITAMIN K; WARFARIN;

EID: 85015880382     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehw496     Document Type: Article

References (22)

1. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22:983-988.
2. Olesen JB, Lip GYH, Lindhardsen J, Lane DA, Ahlehoff O, Hansen ML, Raunsø J, Tolstrup JS, Hansen PR, Gislason GH, Torp-Pedersen C. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: a net clinical benefit analysis using a 'real world' nationwide cohort study. Thromb Haemost 2011;106:739-749.
3. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007;146:857-867.
4. Lip GYH, Lane DA. Stroke prevention in atrial fibrillation a systematic review. JAMA J Am Med Assoc 2015;313:1950-1962.
5. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener H-C, Joyner CD, Wallentin L. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-1151.
6. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KAA, Califf RM. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-891.
7. Granger CB, Alexander JH, McMurray JJV, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FWA, Zhu J, Wallentin L. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981-992.
8. Lynge E, Sandegaard JL, Rebolj M. The Danish National Patient Register. Scand J Public Health 2011;39:30-33.
9. Kildemoes HW, Sørensen HT, Hallas J. The Danish national prescription registry. Scand J Public Health 2011;39:38-41.
10. Pedersen CBC. The Danish civil registration system. Scand J Public Health 2011;39:22-25.
11. Krarup L-H, Boysen G, Janjua H, Prescott E, Truelsen T. Validity of stroke diagnoses in a national register of patients. Neuroepidemiology 2007;28:150-154.
12. Benichou J, Gail MH. Estimates of absolute cause-specific risk in cohort studies. Biometrics 1990;46:813-826.
13. Sato T, Matsuyama Y. Marginal structural models as a tool for standardization. Epidemiology 2003;14:680-686.
14. Tanislav C, Milde S, Schwartzkopff S, Misselwitz B, Sieweke N, Kaps M. Baseline characteristics in stroke patients with atrial fibrillation: clinical trials versus clinical practice. BMC Res Notes 2015;8:262.
15. Lip GYH, Brechin CM, Lane DA. The global burden of atrial fibrillation and stroke: a systematic review of the epidemiology of atrial fibrillation in regions outside North America and Europe. Chest J 2012;142:1489-1498.
16. Madrid AH, Potpara TS, Dagres N, Chen J, Larsen TB, Estner H, Todd D, Bongiorni MG, Sciaraffia E, Proclemer A, Cheggour S, Amara W, Blomstrom-Lundqvist C. Differences in attitude, education, and knowledge about oral anticoagulation therapy among patients with atrial fibrillation in Europe: result of a selfassessment patient survey conducted by the European Heart Rhythm Association. Europace 2016;18:463-467.
17. Staerk L, Fosbøl EL, Gadsbøll K, Sindet-Pedersen C, Pallisgaard JL, Lamberts M, Lip GYH, Torp-Pedersen C, Gislason GH, Olesen JB. Non-vitamin K antagonist oral anticoagulation usage according to age among patients with atrial fibrillation: Temporal trends 2011-2015 in Denmark. Sci Rep 2016;6:31477.
18. Lau Y, Lip G. Which drug should we use for stroke prevention in atrial fibrillation? Curr Opin Cardiol 2014;29:293-300.
19. Wallentin L, Yusuf S, Ezekowitz MD, Alings M, Flather M, Franzosi MG, Pais P, Dans A, Eikelboom J, Oldgren J, Pogue J, Reilly PA, Yang S, Connolly SJ. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. The Lancet 2010;376:975-983.
20. Lauffenburger JC, Farley JF, Gehi AK, Rhoney DH, Brookhart MA, Fang G. Effectiveness and safety of dabigatran and warfarin in real-world US patients with non-valvular atrial fibrillation: a retrospective cohort study. J Am Heart Assoc 2015;4:e001798.
21. Brandes A, Jensen HK, Husted S. NBV 2016-Dansk Cardiologisk Selskab-15. Atrieflimren og atrieflagren. 2016. http://nbv. cardio. dk/af (31 September 2016).
22. Friberg L, Skeppholm M, Terént A. Benefit of anticoagulation unlikely in patients with atrial fibrillation and a CHA2DS2-VASc score of 1. J Am Coll Cardiol 2015;65:225-232.